PL
PLRZ.US Polyrizon Ltd. Ordinary Shares
- Market cap
- USD 26.8M
- P/E
- -
- P/B
- 1.10x
- ROE
- -17.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PLRZ.US undervalued?
Graham numberThe Graham number of Polyrizon Ltd. Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Polyrizon Ltd. Ordinary Shares fundamental analysis
No fundamental analysis for Polyrizon Ltd. Ordinary Shares yet.
Polyrizon Ltd. Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Polyrizon Ltd. Ordinary Shares
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incor…
Full company profilePolyrizon Ltd. Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Polyrizon Ltd. Ordinary Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -1.00K | -6.00K | -5.00K | -4.00K | -118K | -342K | - |
| Operating Income | -72.0K | -703K | -895K | -635K | -1.30M | -6.25M | -13.0M |
| EBITDA | -72.0K | -703K | -772K | -631K | -1.42M | -5.91M | -12.5M |
| Net Income | -73.0K | -711K | -779K | -600K | -1.55M | -3.34M | -4.27M |
| EPS | -0.02 | -0.17 | -0.60 | -215 | -129 | -2.07 | -2.36 |
| Balance Sheet | |||||||
| Total Assets | 24.0K | 687K | 546K | 559K | 5.55M | 21.4M | 24.9M |
| Total Liabilities | 8.00K | 690K | 1.20M | 750K | 261K | 443K | 448K |
| Shareholders' Equity | 16.0K | -3.00K | -652K | 57.0K | 5.29M | 21.0M | 24.4M |
| Cash & Short-term Investments | 10.0K | 523K | 36.0K | 41.0K | 2.55M | 12.3M | 15.0M |
| Total Debt | - | - | 622K | 200K | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -73.0K | -492K | -1.13M | -537K | -1.15M | -4.53M | -5.87M |
| Capital Expenditure | 6.00K | 19.0K | 3.00K | 0.00 | 0.00 | 7.00K | 9.00K |
| Free Cash Flow | -79.0K | -511K | -1.14M | -537K | -1.15M | -4.54M | -5.87M |
| Ratios | |||||||
| ROE | -456.3% | - | - | -1,052.6% | -29.2% | -15.9% | -17.5% |
| ROA | -304.2% | -103.5% | -142.7% | -107.3% | -27.9% | -15.6% | -17.2% |
| Debt to Equity | - | - | - | 3.51x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Polyrizon Ltd. Ordinary Shares dividends
Polyrizon Ltd. Ordinary Shares has not paid dividends in the last 6 fiscal years.
Last stock split: 1:6 on Nov 28, 2025.
Who owns Polyrizon Ltd. Ordinary Shares
- Insiders 0.76%
- Institutions 9.28%
- Public & others 89.97%
- Shares outstanding 2.43M
- Free float 1.87M
Top funds holding PLRZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 823.00 | 0.03% | 0.00% | Aug 2026 |
Top institutions holding PLRZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Mmcap International Inc. Spc | 199K | 8.21% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 21.4K | 0.88% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 1.67K | 0.07% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 11.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Legacy Wealth Managment, LLC/ID | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Polyrizon Ltd. Ordinary Shares company profile
- Company name
- Polyrizon Ltd. Ordinary Shares
- Ticker
- PLRZ.US
- ISIN
- IL0011814113
- Exchange
- USA Stocks
- Listed since
- Oct 29, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 5 HaPnina Street, Ra'anana, Israel, 4321545
- Phone
- 972 9 374 0120
- Website
- polyrizon-biotech.com
About Polyrizon Ltd. Ordinary Shares
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Polyrizon Ltd. Ordinary Shares management
4- Mr. Tomer IzraeliFounder, CEO & Director · born 1978
- Mr. Nir Ben YosefCFO & Compliance Officer · born 1975
- Dr. Tidhar TurgemanChief Technology Officer · born 1976
- Dr. Eyal S. Ron Ph.D.Chief Scientific Officer · born 1955